Document Detail


Advanced meter features improve postprandial and paired self-monitoring of blood glucose in individuals with diabetes: results of the Actions with the CONTOUR Blood Glucose Meter and Behaviors in Frequent Testers (ACT) study.
MedLine Citation:
PMID:  23013200     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: This study evaluated whether education and use of the advanced meter features of the CONTOUR(®) (Bayer HealthCare LLC, Diabetes Care, Tarrytown, NY) blood glucose monitoring system (BGMS) affect the frequency and pattern of blood glucose testing in insulin-using subjects with diabetes who routinely perform self-monitoring of blood glucose (SMBG).
SUBJECTS AND METHODS: Insulin-using subjects with type 1 or type 2 diabetes were enrolled in this 6-month, multicenter, prospective study and randomized to one of two groups. The basic meter features group (BMF group) received basic instruction in the use of the BGMS, whereas the advanced meter features group (AMF group) also received training in the use of advanced features, including the meal marker and audible reminder, and were instructed to use these features. Both groups received education on the importance of postprandial testing.
RESULTS: The AMF group (n=105) had significantly greater average weekly postprandial blood glucose testing than the BMF group (n=106) at each follow-up visit (P<0.001) and significantly increased the frequency of paired blood glucose testing (P<0.001) as well. In both groups, glycated hemoglobin decreased significantly as postprandial testing frequency increased (P<0.05). Subject reports indicated that use of advanced features made postmeal SMBG considerably easier to remember, helped them better understand how to make decisions on their own, and increased their confidence in meal choices.
CONCLUSIONS: Study findings showed that advanced features of the CONTOUR BGMS increased structured testing as measured by postprandial and paired SMBG and were perceived as useful by patients.
Authors:
Richard M Bergenstal; Bruce W Bode; Ronald Tamler; Dace L Trence; Patricia Stenger; Holly C Schachner; Jeanellen Fullam; Scott Pardo; Taylor Kohut; William A Fisher
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  14     ISSN:  1557-8593     ISO Abbreviation:  Diabetes Technol. Ther.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-27     Completed Date:  2013-02-12     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  851-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Albuminuria / blood
Blood Glucose / metabolism
Blood Glucose Self-Monitoring* / statistics & numerical data
Diabetes Mellitus, Type 1 / blood*,  drug therapy,  epidemiology
Diabetes Mellitus, Type 2 / blood*,  drug therapy,  epidemiology
Female
Follow-Up Studies
Health Behavior*
Hemoglobin A, Glycosylated / metabolism
Humans
Hypoglycemic Agents / therapeutic use*
Insulin / therapeutic use*
Male
Middle Aged
Patient Compliance
Postprandial Period
Prospective Studies
United States / epidemiology
Young Adult
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Insulin; 0/hemoglobin A1c protein, human
Comments/Corrections
Comment In:
Diabetes Technol Ther. 2012 Oct;14(10):849-50   [PMID:  23013199 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Influence of Hyperthermophilic Protein Cren7 on the Stability and Conformation of DNA: Insights from...
Next Document:  Use of continuous glucose monitoring as an outcome measure in clinical trials.